New MS biosimilar aims to match leading Drug's effect

NCT ID NCT06847724

Recruiting now Disease control Sponsor: Sandoz Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 27 times

Summary

This study tests whether a new drug called CYB704 works as well as the approved drug Ocrevus for people with relapsing multiple sclerosis (MS). About 175 adults with active MS will receive either CYB704 or Ocrevus and be monitored with regular checkups and MRI scans. The goal is to see if the two drugs have similar levels in the body, similar effects on MS lesions, and similar safety profiles.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sandoz Investigational Site
RECRUITING

Maitland, Florida, 32751, United States
Sandoz Investigational Site
RECRUITING

Ormond Beach, Florida, 32174, United States
Sandoz Investigational Site
RECRUITING

Banja Luka, Bosnia and Herzegovina
Sandoz Investigational Site
RECRUITING

Bihać, Bosnia and Herzegovina
Sandoz Investigational Site
RECRUITING

Sarajevo, Bosnia and Herzegovina
Sandoz Investigational Site
RECRUITING

Pleven, Bulgaria
Sandoz Investigational Site
RECRUITING

Plovdiv, Bulgaria
Sandoz Investigational Site
RECRUITING

Sofia, Bulgaria
Sandoz Investigational Site
RECRUITING

Varaždin, Croatia
Sandoz Investigational Site
RECRUITING

Zagreb, Croatia
Sandoz Investigational Site
RECRUITING

Rustavi, Georgia
Sandoz Investigational Site
RECRUITING

Tbilisi, Georgia
Sandoz Investigational Site
RECRUITING

Shtip, North Macedonia
Sandoz Investigational Site
RECRUITING

Skopje, North Macedonia
Sandoz Investigational Site
RECRUITING

Bydgoszcz, Poland
Sandoz Investigational Site
RECRUITING

Katowice, Poland
Sandoz Investigational Site
RECRUITING

Lodz, Poland
Sandoz Investigational Site
RECRUITING

Lublin, Poland
Sandoz Investigational Site
RECRUITING

Nowa Sól, Poland
Sandoz Investigational Site
RECRUITING

Poznan, Poland
Sandoz Investigational Site
RECRUITING

Szczecin, Poland
Sandoz Investigational Site
RECRUITING

Warsaw, Poland
Sandoz Investigational Site
RECRUITING

Zabrze, Poland
Sandoz Investigational Site
RECRUITING

Belgrade, Serbia
Sandoz Investigational Site
RECRUITING

Niš, Serbia
Sandoz Investigational Site 2
RECRUITING

Sarajevo, Bosnia and Herzegovina
Sandoz Investigational Site 2
RECRUITING

Plovdiv, Bulgaria
Sandoz Investigational Site 2
RECRUITING

Sofia, Bulgaria
Sandoz Investigational Site 2
RECRUITING

Tbilisi, Georgia
Sandoz Investigational Site 2
RECRUITING

Katowice, Poland
Sandoz Investigational Site 2
RECRUITING

Poznan, Poland
Sandoz Investigational Site 3
RECRUITING

Sofia, Bulgaria
Sandoz Investigational Site 3
RECRUITING

Tbilisi, Georgia
Sandoz Investigational Site 4
RECRUITING

Sofia, Bulgaria
Sandoz Investigational Site 4
RECRUITING

Tbilisi, Georgia
Sandoz Investigational Site 5
RECRUITING

Sofia, Bulgaria
Sandoz Investigational Site 5
RECRUITING

Tbilisi, Georgia
Sandoz Investigational Site 6
RECRUITING

Tbilisi, Georgia
Sandoz Investigational Site 7
RECRUITING

Tbilisi, Georgia
Sandoz Investigational Site 8
RECRUITING

Tbilisi, Georgia

Conditions

Explore the condition pages connected to this study.

RELAPSING MULTIPLE SCLEROSIS